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Tuberculosis (TB) is one of the top 10 causes of mortality and morbidity. Worldwide, yet, it has been over 60 years since a novel drug was 
introduced in market to treat the disease exclusively. Increased number of drug resistant TB cases has prompted the search for novel potent 
anti-TB drug. Mycobacterial cell wall has unique structure which provides integrity to the cell. The future development of new potent anti-TB 
drug targets is associated with the synthesis of various cell wall constituents; the structural and genetic information about mycobacterial cell 
wall envelope is now available. In the present review, we have focused on prospective drug targets that can be optimum triumph for successful 
drug candidate.
INTRODUCTION
Tuberculosis (TB), the infection caused by Mycobacterium species, 
is the major disease across the globe. There are three species of 
mycobacteria which are prominently observed in major population 
of patients. The species are Mycobacterium tuberculosis (Mtb), 
Mycobacterium avium, and Mycobacterium smegmatis out of which 
Mtb infection is more common. TB is one of the top 10 causes of death 
worldwide. According to recent World Health Organization’s report, 
over 10 million people get infected with TB. Despite widespread use 
of BCG vaccine, TB infection has not been reduced as compared to 
other diseases [1].
The disease has reemerged as growing global health problem not 
only because of lack of proper therapeutic agents but also due to 
the development of drug resistance by mycobacterial strains. The 
emergence of multidrug-resistant (MDR) and extremely drug resistance 
(XDR) strains of this lethal pathogen renders current treatment 
strategies very difficult, and in some cases, there is complete failure [2]. 
Thus, the development of new anti-TB drug is an urgent need. The 
unrevealing of mycobacterial cell wall envelope has given new key to 
successful development of anti-TB drugs. The review describes about 
overview of current treatment its drawback and future prospective of 
drug development against TB infection.
CATEGORIES OF TB INFECTIONS
There are four categories of TB infection. Primary infection Category 
I belongs to new cases of sputum smear-positive pulmonary or 
extrapulmonary TB infection. Category II belongs to patients which are 
defaulted, irregularly treated, or sometimes relapsed. Category III is 
MDR TB where the patient is resistant to rifampicin which is given orally 
and needs further injectables and fluoroquinolones with combination. 
Category IV is extensively XDR TB which is resistant to two first-line 
agents (isoniazid and rifampicin), to any one fluoro-quinolone, and to 
any one second-line drug like amikacin [3].
TB ASSOCIATED WITH OTHER INFECTIONS
M. avium complex (MAC)
MAC is an atypical mycobacterial infection, that is, one with non-
tuberculous mycobacteria which consists of two mycobacterial species 
M. avium and Mycobacterium intracellulare. This infection causes 
respiratory illness in patients, especially in immunocompromised 
people. It is also called as opportunistic infection, because it develops 
when cell-mediated immunity is markedly depressed (CD4 count drops 
to <50 cells/µL).
CURRENT SCENARIO OF TB INFECTION
At present, 10.0 million people around the world acquire TB disease, 
out of which 1 million cases occurred in infants and children. 
1.6  million TB-related deaths worldwide including 0.3 million 
infected with HIV. Multidrug-resistant TB (MDR-TB) remains a public 
health crisis, the WHO estimated that there were 0.6 million new cases 
with resistance to rifampicin. About 82% had MDR-TB. Globally, TB 
incidence is declining about 2% per year, which should be accelerated 
to 4–5% to reduce TB risk. The summarized view of statistical data is 
depicted in Fig. 1.
CURRENT TB THERAPY
The current TB treatment is based on guidelines of the World Health 
Organization. According to clinical utility, the anti-TB drugs are divided 
into five groups as described below.
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Human immunodeficiency virus (HIV)
Risk of the development of TB in HIV-infected patients is around 
25 times greater than normal people due to patient’s compromised 
immunity. The HIV-infected patients develop early resistance to the 
first-line TB agents due to drug interactions between medicines of both 
diseases. About 60% of TB cases associated with HIV-infected people 
results in early critical conditions with death of patient.
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Group I (First-line agents)
These drugs have high efficacy as well as low toxicity they are used 
routinely. The drugs are isoniazid (H), rifampicin (R), pyrazinamide (Z), 
ethambutol (E), and streptomycin (S).
Group II (Injectable drugs)
These are various types of antibiotics which are prescribed for MDR 
and XDR TB. They are administered through intravenous or other 
parenteral routes. Commonly used drugs are kanamycin (Km), amikacin 
(Am), and capreomycin (Cm).
Group III (Fluoroquinolones)
The most popular antibacterial of quinolone class are used in case of 
MDR-TB when patients develop resistance for first-line and second-
line agents. The commonly used fluoroquinolones are ofloxacin (Ofx), 
levofloxacin (Lfx), moxifloxacin (Mfx), and ciprofloxacin (Cfx).
Group IV (Second-line agents)
These drugs have low efficacy or high toxicity or both and are used as 
reserve drugs. The drugs are ethionamide (Eto), prothionamide (Pto), 
cycloserine (Cs), trazodone (Trd), para-amino salicylic acid (PAS), 
rifabutin, and thiacetazone (Thz).
Group V (Drugs with unclear efficacy)
These drugs are used when the patient develops XDR-TB phase of 
infection. These are broad spectrum antibiotics such as broad-spectrum 
penicillins, sulfonamides, and macrolide antibiotics. Commonly used are 
amoxicillin/clavulanic acid, thiacetazone, clarithromycin, clofazemine, 
linezolid, and imipenem [4-8]. The common anti-TB drugs with their 
mode of action, binding site, and category are summarized as depicted 
below (Fig. 2 and Table 1).
The anti-TB agents are prescribed in combination as per the guidelines 
given by the WHO. The Directly Observed Therapy Short-course (DOTS) 
program is followed for the treatment of TB. The patients are grouped 
according to site and severity of disease, sputum smear condition, and 
patient history. The DOTS therapy regimen is summarized in Table 2.
TARGETS OF ANTI-TB TREATMENT
Although the disease having wide range of drugs serving the treatment, 
still there is a need to develop new drug candidate as the current 
treatment is having two major problems one is discontinuation 
of therapy by patient due to longer duration of time and second 
is the development of resistance to maximum drug candidates by 
mycobacterial strains over the period. For the development of drugs, the 
research has new dimension of genomics which provide information 
about the nature of enzymes and metabolites of the pathogens, which 
will help to design scaffold for potential drug targets. To develop 
new anti-TB drug, mycobacterial cell envelope is attractive core. 
Mycobacteria have unique cell wall structure, which regulates major 
cell functions. The mycobacterial cell has been explored for enzymatic 
and genomic pathways which can be targeted for drug discovery in 
the past few years numerous gene targets have been explored for the 
anti-tubercular drug development across the globe. Out of which cell 
wall synthesis/cell envelope was the prime target for researchers. 
The targets are classified based on its presence in the cell wall [9,10]. 
To understand the targets, study of components of cell membrane of 
the mycobacteria is to be done. The mycobacterial cell wall primarily 
comprises arabinogalactan, peptidoglycan, and mycolic acid. Other 
than these components, it contains carrier proteins, carbohydrates, 
and lipids. The detailed structure of mycobacterial cell membrane is 
described in the diagram below (Fig. 3).
COMPONENTS OF MYCOBACTERIAL CELL WALL
Chiaradia et al. examined the mycobacterial cell membrane by 
transmission electron microscopy and biochemical analysis. The results 
determined composition of the mycobacterial cell wall. It contains more 
than 2100 proteins between plasma membrane and mycobacterial cell 
wall. Among these, the mannosyl transferase (PimB), galactofuranosyl 
transferase (GlfT2), Cytochrome p450, and ABC transporter (YjfF) were 
Fig. 1: Statistical evaluation of tuberculosis infection
Fig. 3: Mycobacterial cell wall structure. MM: Trehalose 
monomycolates; PIM: Phosphatidyl-myo-inositol mannosides; 
GPL: Glycopeptidolipids; TDM: Trehalose dimycolates; 
LAM: Lipoarabinomannans; Ag85: Antigen 85; PL: Phospholipids; 
TAG: Triacylglycerols
Fig. 2: Popular anti-TB drugs. (a: Isoniazid, b: Pyrazinamide, c: 
Ethambutol, d: Ciprofloxacin, e: D-cycloserine, f: p-Amino Salicylic 
acid, g: Ciprofloxacin, h: Streptomycin)
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most abundant in the plasma membrane. Plasma membrane also contains 
lipoglycans, phospholipids including phosphatidylinositol mannosides, 
and other glycolipids [11]. Antigen 85 complex proteins, porins, putative 
transporters, and mammalian cell entry protein family were mostly found 
in mycobacterial cell wall fraction that contains mycolic acid esterifying 
arabinogalactan constituting the inner leaflet of mycomembrane, along 
with glycolipids, phospholipids, lipoglycans, and proteins [12].
The cell wall of mycobacteria contains outermost layer (OL) which 
constitutes proteins with carbohydrate and negligible amount of 
lipids. After the OL layer of mycolic acid, mycomembrane (MM), 
arabinogalactan (AG), and peptidoglycan (PG) are present, respectively. 
The inner leaflet of the MM is made of very long-chain fatty acids 
(mycolic acids) esterifying (AG), covalently attached to (PG). The outer 
leaflet of the MM is presumably composed of lipids extractable with 
organic solvents, which includes phospholipids, trehalose mycolates, 
glycopeptidolipids, and lipoglycans. A periplasmic space separates 
the cell wall from the conventional lipid bilayer of plasma membrane 
(PM) of phospholipids and proteins. The cell envelop has different 
components regulated by various enzymes. The enzymes are primary 
targets for cell wall inhibition. Mycolic acid metabolism is considered 
as upcoming target related to mycolic acid [13].
Table 1: Popular anti-TB drugs with mode of action and mechanism of resistance
S. 
No.
Drug Route of 
administration
Action against Primary binding site 
and mechanism of 
action 











KatG, inhibition of cell 
wall synthesis (mycolic 
acid)
Inhibition of InhA and KasA 
by binding with NAD, as 
well inhibits mycobacterial 
DHFRase by binding with 
NADP
Mutation in 
KatG, InhA, and 
KasA




RpoB, interfere with 
mycobacterial DNA 
function
Interruption of RNA 
synthesis by binding to 





3. Pyrazinamide (Z) Oral Intracellular and at 
inflamed sites
pncA, inhibition of cell 
wall synthesis (mycolic 
acid)
Get converted to pyrazinoic 
acid and accumulates in 
acidic medium, results in 
inhibition of mycolic acid 
synthesis
Mutation in pncA
4. Ethambutol (E) Oral Intracellular and fast 
multiplying bacteria
Emb AB, inhibition of cell 
wall synthesis (mycolic 
acid)
Inhibition of arabinosyl 
transferases, involves in 
arabinogalactan synthesis 




5. Streptomycin (S) Intramuscular Extracellular 30S ribosome, interfere 
with protein synthesis
Inhibition of protein 
synthesis prevent 
polysome formation, 













DNA gyrase A subunit, 
Inhibition of bacterial 
DNA gyrase
Binds with A subunit 
and interfere with strand 






7. Ethionamide (Eto), 
Prothionamide (Pto)
Oral Intracellular and 
Extracellular
ethA, inhibition of cell 
wall synthesis (mycolic 
acid)
Binds NAD+ to form adduct 
which inhibits InhA in the 
same way as isoniazid. The 
mechanism of action is 





8. Cycloserine (Cs) Oral Intracellular and 
extracellular
Alanine racemase, 
inhibition of cell 
wall biosynthesis 
(Peptidoglycan)
Inhibition of bacterial 
cell wall synthesis by 
inactivating the enzymes 
which racemize L-alanine 




9. Para-amino salicylic 
acid (PAS)
Oral Extracellular and 
intracellular, fast 
multiplying bacteria
Inhibition of folic acid 
synthesis
Incorporated into the folate 
pathway DHPS and DHFS
Injectable agents






interfere with protein 
synthesis
Inhibition of protein 
synthesis prevent 
polysome formation, 




binding site of 
ribosomes
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Peptidoglycan biosynthesis
Peptidoglycan is the essential cell wall component of mycobacterial 
cell wall which gives rigidity to cell. Peptidoglycan consists of N-Acetyl 
Glucosamine (NAG), N-Glycolyl muramic acid (NAM), and alanine 
(Al). The peptidoglycan biosynthesis is targeted for anti-TB drug 
development from decades but still any drug candidate other than 
D-clycoserine has not shown promising effect, D-cycloserine inhibits 
peptidoglycan biosynthesis by inhibiting essential enzymes alanine 
racemase (Alr) and D-Ala-D-Ala ligase. It was predicted that bacitracin 
antibiotic also targets peptidoglycan biosynthesis but exact mechanism 
is not known. Another target in peptidoglycan synthesis is glutamate 
racemase for which β-chloro-D-alanine and its derivatives are 
under study, the exact mechanism is not identified but the enzyme is 
considered as potential target. The peptidoglycan biosynthesis can be 
inhibited by alanine like small molecules which can act as competitive 
inhibitor of alanine inhibiting attachment of alanine to NAG and NAM to 
form peptidoglycan [14-18].
Arabinogalactan biosynthesis
The arabinogalactan layer is present just next to the peptidoglycan layer. 
It contains sugars like rhamnose, galactose, phospholipids, and carrier 
proteins. The next important target in the mycobacterial cell wall is 
arabinogalactan synthesis. Ethambutol is the one of the extensively 
used anti-TB drugs which act through inhibition of arabinogalactan 
synthesis through inhibition of arabinosyltransferase enzyme.
Uridine diphosphate-galactopyranose (UDP-galactopyranose) is also 
identified as important enzyme in this pathway which involves in 
attachment of galactose in the arabinogalactan. Recent studies reported 
that the biosynthesis of the cell wall galactan of mycobacteria through 
Rv3808c protein can be inhibited through galactosyl transferase 
enzymes. Decaprenyl phosphorylase-2-epimerases are challenging 
target in the mycobacterial synthesis because targeting this enzyme 
has many challenges due to its oxidoreductive property responsible 
for degeneration of chemical structure of drug. A prodrug approach 
toward the drug development can be considered as novel way to target 
the enzyme, benzothiazinone which inhibits the enzyme and is under 
clinical investigation. From the description of enzymes, one can predict 
small cyclic molecules with structural similarity to galactose with 
hetero-atoms as potent candidates to target the pathway [19-21].
Mycolic acid biosynthesis and metabolism
Mycolic acid is unique feature of mycobacteria it is fatty acid containing 
carbon chain of 70 carbons. It makes the mycobacteria more resistant to 
chemical damage and dehydration. It also helps mycobacteria to grow 
inside the macrophages by effectively hiding from host immune system.
There are four types of enzymes related to mycolic acid:
1. Fatty acid synthesis I (FAS I): Ketoacyl-ACP synthases, Catalase-
peroxidase
2. Fatty acid synthesis II (FAS II): ENR enoyl acyl carrier protein 
reductase, EthA gene
3. Fatty acid synthesis condensing enzymes: polyketide synthase 
(Pks13) and fatty acid desaturase (FAD13/FAD32)
4. Mycolic acid metabolism: Mycobacterial membrane protein large 
(mmpL), mycobacterial membrane protein small (mmpS).
Fatty acid synthesis I pathway (FAS I)
The pathway includes synthesis of C26 straight chain fatty acids, which 
involves enzymes such as Ketoacyl-ACP synthases (CasA) and Catalase-
peroxidase (KatG). The enzymes are inhibited by popular drugs such 
as isoniazid, pyrazinamide, and ethionamide. The drugs are susceptible 
to resistance due to mutations in genes regulating the enzyme. The 
ketoacyl-ACP synthases enzyme is indirectly involved in mechanism of 
many drugs but direct target for the enzyme is under study. The KatG is 
involved in activation of isoniazid into isoform to the anion of nicotinic 
acid, which further inhibits the cell all synthesis by inhibiting FAS II 
pathway competitively. FAS I pathway can be inhibited by chemical 
moieties such as thiazolidine linezolid and heterocyclic five and six-
membered derivatives [22,23].
Fatty acid synthesis II pathway (FAS II)
The pathway further involves in chain elongation and addition of 
functional groups to the chain. It involves enzymes such as enoyl acyl 
carrier protein reductase (InhA) and EthA gene. The well-known drug 
isoniazid inhibits (InhA) enzymes after activation by KatG. EthA gene is 
another target on the FAS II pathway which is inhibited by ethionamide. 
To inhibit FAS II pathway, there are many chemically and biologically 
important scaffolds such as epigallocatechin gallate, luteolin, cinnamic 
acid derivatives, quinones, thiocarbamides, and diphenyl ether [24,25].
Fatty acid synthesis condensing pathway
The pathways involve condensation and attachment of mycolic acid to 
arabinogalactan layer. The enzymes involved in pathway are polyketide 
synthase (Pks13) and fatty acid desaturase (Fad13/Fad32). The 
pathways are not having any current potential anti-TB targets. However, 
there are numerous drugs and enzyme pathways such as acyl-adenylate 
monophosphate ligase (acyl-AMP ligase), FadD32, acyl-coenzyme A 
(CoA) carboxylase. Benzofuran, thiophene, and coumarin derivative 
inhibit the fatty acid synthesis condensing pathway [26].
Mycolic acid metabolism pathway
The mycolic acid metabolism is indirectly involved in mechanism of 
many antitubercular drugs and has important function of the drug influx 
Table 2: Category wise treatment regimens for TB
Category Intensive phase Continuous phase Duration 
(months)
Comment
I New patient 2$ HRZE daily 4$ HR daily 6$ Optimal
2 HRZE daily 4$ HR thrice weekly 6 Acceptable if DOT ensured
2 HRZE thrice weekly 4$ HR thrice weekly 6 Acceptable if DOT ensured
II Previously treated 
patients pending 
DST result
2 HRZES daily + 1 HRZE daily 5 HRE daily 8 For patient with low/medium risk of 
MDR-TB
(failure, default)
Empirical£ (standardized) MDR-regimen Empirical 
(standardized) MDR-
regimen
18-24 Or till DST 
results
For patients with high risk of MDR-TB 
(failure, 2nd default, contact of MDR-
TB)
III MDR-TB 6-9 Any 4 of Km, Ofx/Lfx, Eto, Cs, Z, E, 
PAS + Pyridoxine 100 mg/day
18 Any 4 of Ofx/
Lfx, Eto, Cs, E, 
PAS + Pyridoxine 
100 mg/day
24-27 For patients with failure to 1st line and 
2nd line treatment
IV XDR-TB Group V drugs are prescribed according to the severity of infection for unpredicted period of time.
DST: Drug sensitivity testing; DOT: Directly observed therapy; $- The numerals indicate duration of phase, £- Empirical (standardization) MDR regimen is country 
depending on local data and situation.
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Table 3: Summary of enzyme targets in mycobacterial cell wall synthesis
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in mycobacteria. The acid associated pathways can be explored through 
different scaffolds such as cinnamic acid, thiazolidine, rhodanine 
scaffolds, and many other natural products [27-37]. Summary of 
enzyme targets is depicted in Table 3.
ANTI-TB SCAFFOLDS IN PIPELINE
The era of anti-TB drug development is rapidly changing from phenotypic 
to genotypic research. Till date, numerous scaffolds are explored for 
this purpose. The scaffolds screened are ranging from NCE’s obtained 
from natural sources, biological extracts, and enzymes from genetically 
modified microorganisms and from synthetic sources. In the past 10 years, 
various scaffolds from synthetic source such as β-chloro-D-alanine, 
ethers, dinitrobenzamide (benzothiazinone), linezolid, thiocarbamides, 
cinnamic acid, benzofuran, and quinazolinones derivatives are used. Few 
natural products such as epigallocatechin, quinines, and coumarins are 
also explored for the development of new drug.
CONCLUSION
Today, it is very important to develop new anti-TB drugs. With the help 
of enzymatic and genetic pathways, we can achieve target-based drug 
development which will be helpful to overcome the problems associated 
with existing anti-TB therapy. The unique structure of mycobacterial 
cell wall makes it ideal for target-based drug development. The 
architecture of the mycobacterial cell wall is complex and represents 
a substantial permeability barrier that is made up of a wide variety 
of compounds including mycolic acids, free lipids, polysaccharides, 
glycolipids, and lipoarabinomannan. Many of these components are 
genera or species specific. Most of the existing anti-TB drug candidates 
targets cell wall to inhibit bacterial growth. Nevertheless, none of the 
known cell wall synthesis inhibitors are endowed with rapidly acting 
sterilizing activity, hence, these drugs are urgently needed in TB 
control programs. All apparently require actively replicating bacteria 
for efficacy. A problematic issue one addresses latent TB, a condition 
in which mycobacteria are not actively dividing or synthesizing cell 
wall component which is apparently prevalent in about one-third of 
the global population. At present, the anti-TB drug development should 
be focused on potent drug candidates who can withstand to MDR TB. 
The novel drug development includes targeting unexplored cell wall 
components for drug development, shortening duration of existing 
drug therapy, development of potent anti-TB drugs, and repurposing of 
old drugs.
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